Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes

Epidemiology and Infection

Volumn 140, Issue 7, 2012, Pages 1267-1276

  Song, J S ^a   Choe, P G ^a   Song, K H ^a   Park, W B ^a   Park, S W ^a   Kim, H B ^a   Oh, M D ^a   Kim, E C ^a   Kim, N J ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Antibiotic resistance; pneumococcal infection; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; PENICILLIN G; RIFAMPICIN; TETRACYCLINE;

ADULT; AGED; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APACHE; ARTICLE; BACTERIAL STRAIN; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GRAM STAINING; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMOCOCCAL INFECTION; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SOUTH KOREA; STREPTOCOCCUS PNEUMONIAE; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861097323     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811001816     Document Type: Article

References (36)

1. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 2002; 50 (Suppl.) : 1-5.
2. Song JH, et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries : Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clinical Infectious Diseases 1999; 28: 1206-1211.
3. Whitney CG, et al. Increasing prevalence of multidrugresistant Streptococcus pneumoniae in the United States. New England Journal of Medicine 2000; 343: 1917-1924.
4. Metlay JP, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clinical Infectious Diseases 2000; 30: 520-528.
5. Poole MD. Otitis media complications and treatment failures : Implications of pneumococcal resistance. Pediatric Infectious Diseases Journal 1995; 14: S23-26.
6. Sloas MM, et al. Cephalosporin treatment failure in penicillin-And cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatric Infectious Diseases Journal 1992; 11: 662-666.
7. Kelley MA, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 2000; 31: 1008-1011.
8. Lonks JR, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycinresistant Streptococcus pneumoniae. Clinical Infectious Diseases 2002; 35: 556-564.
9. Van Kerkhoven D, et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. Journal of Antimicrobial Chemotherapy 2003; 51: 691-696.
10. Davidson R, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. New England Journal of Medicine 2002; 346: 747-750.
11. Moroney JF, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clinical Infectious Diseases 2001; 33: 797-805.
12. Yu VL, et al. An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clinical Infectious Diseases 2003; 37: 230-237.
13. Song JH, et al. Spread of multidrug-resistant Streptococcus pneumoniae in South Korea. Clinical Infectious Diseases 1997; 25: 747-749.
14. Song JH, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries : A study by the Asian Network for Surveillance of Resistant Pathogens. Clinical Infectious Diseases 2004; 38: 1570-1578.
15. Song JH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrobial Agents and Chemotherapy 2004; 48: 2101-2107.
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing : 18th informational supplement. Wayne, PA, USA: CLSI, 2008; CLSI document M100-S18.
17. Knaus WA, et al. APACHE II : A severity of disease classification system. Critical Care Medicine 1985; 13: 818-829.
18. Dahmash NS, Chowdhury NH, Fayed DF. Septic shock in critically ill patients : Aetiology, management and outcome. Journal of Infection 1993; 26: 159-170.
19. Harbarth S, Garbino J. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulation therapy for severe sepsis. American Journal of Medicine 2003; 115: 529-535.
20. Doern GV, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States : Have we begun to turn the corner on resistance to certain antimicrobial classes ? Clinical Infectious Diseases 2005; 41: 139-148.
21. Lynch 3rd JP, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: Implications for therapy. Seminars in Respiratory and Critical Care Medicine 2005; 26: 575-616.
22. Pallares R, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine 1995; 333: 474-480.
23. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: Coping with antimicrobial susceptibility in an era of resistance. Clinical Infectious Diseases 2009; 48: 1596-1600.
24. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infectious Disease Clinics of North America 2003; 17: 479-501.
25. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clinical Infectious Diseases 1998; 26: 1346-1354.
26. Hsueh PR, et al. Telithromycin-And fluoroquinoloneresistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and betalactams: SMART program 2001 data. Antimicrobial Agents and Chemotherapy 2003; 47: 2145-2151.
27. Waites KB, et al. Dissemination of macrolide-resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) in South Korea. Journal of Clinical Microbiology 2003; 41: 5787-5791.
28. Ko KS, Song JH. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. Journal of Infectious Diseases 2004; 190: 739-747.
29. Aspa J, et al. Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors. Clinical Infectious Diseases 2004; 38: 787-798.
30. Kim BN, et al. Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia. European Journal of Clinical Microbiology and Infectious Diseases 2002; 21: 35-42.
31. Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: Epidemiology, risk factors, and strategies for prevention. Seminars in Respiratory and Critical Care Medicine 2009; 30: 189-209.
32. Turett GS, et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clinical Infectious Diseases 1999; 29: 321-327.
33. Falco V, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: Is penicillin useful against intermediately resistant strains ? Journal of Antimicrobial Chemotherapy 2004; 54: 481-488.
34. Song JH, et al. Epidemiology and clinical outcomes of community-Acquired pneumonia in adult patients in Asian countries : A prospective study by the Asian network for surveillance of resistant pathogens. International Journal of Antimicrobial Agents 2008; 31: 107-114.
35. Feikin DR, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. American Journal of Public Health 2000; 90: 223-229.
36. Metlay JP. Antibacterial drug resistance : Implications for the treatment of patients with community-Acquired pneumonia. Infectious Disease Clinics of North America 2004; 18: 777-790.